Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Colombian And Mexican Presidents Announce International Effort To Reshape Drug Policy, Condemning ‘Failure’ Of Prohibition
https://www.marijuanamoment.net/colombian-and-mexican-presidents-announce-international-effort-to-reshape-drug-policy-condemning-failure-of-prohibition/
Marijuana Businesses on track to start retail sales
https://420intel.com/articles/2022/11/28/marijuana-businesses-track-start-retail-sales
Canadian producers destroyed over 500 tons of cannabis since 2018
Have you not read any Canadian polls or know how your investment money has been lost?
Everyone wants legalization and no one to be treated like a criminal for cannabis, but over 60% polled are non-users, non-buyers, and anti-weed protestors.
Your comments are all speculations and hype
and my fact based news says
supply and inventories are 1000 X demand
https://mjbizdaily.com/canadian-producers-destroyed-over-500-tons-of-cannabis-since-2018/
New Poll Shows 9 Out Of 10 Americans Support Legal Pot
https://hightimes.com/news/new-poll-shows-9-out-of-10-americans-support-legal-pot/
Americans overwhelmingly say marijuana should be legal for medical or recreational use
https://www.pewresearch.org/fact-tank/2022/11/22/americans-overwhelmingly-say-marijuana-should-be-legal-for-medical-or-recreational-use/
Rhode Island Recreational Marijuana Sales Will Start Next Week, Governor Announces
https://www.marijuanamoment.net/rhode-island-recreational-marijuana-sales-will-start-next-week-governor-announces/
naive , optimistic people think that access to USA market creates new opportunity
for Canopy ..... when the truth is - american market is already over supplied !
Nov 17 2022
Jeffrey Galvin
Global consumption of marijuana is increasing, but there is a paucity of evidence concerning associated lung imaging findings.
Purpose
To use chest CT to investigate the effects of marijuana smoking in the lung.
Materials and Methods
This retrospective case-control study evaluated results of chest CT examinations (from October 2005 to July 2020) in marijuana smokers, nonsmoker control patients, and tobacco-only smokers. We compared rates of emphysema, airway changes, gynecomastia, and coronary artery calcification. Age- and sex-matched subgroups were created for comparison with tobacco-only smokers older than 50 years. Results were analyzed using ?2 tests.
Results
A total of 56 marijuana smokers (34 male; mean age, 49 years ± 14 [SD]), 57 nonsmoker control patients (32 male; mean age, 49 years ± 14), and 33 tobacco-only smokers (18 male; mean age, 60 years ± 6) were evaluated. Higher rates of emphysema were seen among marijuana smokers (42 of 56 [75%]) than nonsmokers (three of 57 [5%]) (P < .001) but not tobacco-only smokers (22 of 33 [67%]) (P = .40). Rates of bronchial thickening, bronchiectasis, and mucoid impaction were higher among marijuana smokers compared with the other groups (P < .001 to P = .04). Gynecomastia was more common in marijuana smokers (13 of 34 [38%]) than in control patients (five of 32 [16%]) (P = .039) and tobacco-only smokers (two of 18 [11%]) (P = .040). In age-matched subgroup analysis of 30 marijuana smokers (23 male), 29 nonsmoker control patients (17 male), and 33 tobacco-only smokers (18 male), rates of bronchial thickening, bronchiectasis, and mucoid impaction were again higher in the marijuana smokers than in the tobacco-only smokers (P < .001 to P = .006). Emphysema rates were higher in age-matched marijuana smokers (28 of 30 [93%]) than in tobacco-only smokers (22 of 33 [67%]) (P = .009). There was no difference in rate of coronary artery calcification between age-matched marijuana smokers (21 of 30 [70%]) and tobacco-only smokers (28 of 33 [85%]) (P = .16).
Conclusion
Airway inflammation and emphysema were more common in marijuana smokers than in nonsmokers and tobacco-only smokers, although variable interobserver agreement and concomitant cigarette smoking among the marijuana-smoking cohort limits our ability to draw strong conclusions.
© RSNA, 2022
See also the editorial by Galvin and Franks in this issue.
Download as PowerPoint
Summary
In this case-control study of marijuana smokers, nonsmokers, and tobacco-only smokers, smoking marijuana was associated with paraseptal emphysema, bronchiectasis, bronchial wall thickening, and airway mucoid impaction.
Key Results
¦ In this retrospective case-control study analyzing chest CT findings in 56 marijuana smokers, 57 nonsmokers, and 33 tobacco-only smokers, marijuana smokers had higher rates of airway changes than did tobacco-only smokers or nonsmokers (P < .001 to P = .04).
¦ Emphysema was more common in marijuana smokers than in nonsmokers (75% vs 5%, P < .001) and in age- and sex-matched marijuana smokers than in tobacco-only smokers (93% vs 67%, P = .009); the paraseptal subtype of emphysema was predominant in marijuana smokers.
Introduction
Marijuana is the most widely used illicit psychoactive substance in the world (1) and the second-most commonly smoked substance after tobacco (2). Its use has increased in Canada since the legalization of nonmedical marijuana in 2018. In 2020, 20% of the population in Canada aged at least 15 years reported having used marijuana in the previous 3 months compared with 14% of the population before marijuana legalization (3). In the United States, the percentage of all adults reporting marijuana use within the previous year rose from 6.7% in 2005 to 12.9% in 2015 (4).
Marijuana is consumed via multiple routes, including smoking, vaporizing, and eating, with inhaled methods being the most common (5). It may be smoked by itself or mixed with tobacco. It is usually smoked without a filter, and users inhale larger volumes with a longer breath hold compared with tobacco smokers (6). For measures of airflow obstruction, one marijuana joint can produce an effect similar to that of 2.5–5.0 tobacco cigarettes (7). Marijuana smoke contains known carcinogens and other chemicals associated with respiratory diseases (8).
Numerous studies have focused on the relationship of marijuana to pulmonary function tests, symptoms, and lung cancer. Two recent systematic reviews (2,9) determined that heavy marijuana use can lead to respiratory symptoms similar to those in tobacco smokers, including cough, sputum production, and wheeze. These are likely related to inflammation of the tracheobronchial mucosa (10) and mucus hypersecretion (11). One study posits that although marijuana causes bronchitis in current users, it does not lead to irreversible airway damage (6). The relationship of marijuana use to pulmonary function test results and lung cancer occurrence is described as equivocal, and both review studies comment on the possibility of the bronchodilatory effect of chronic marijuana smoking leading to a long-term increase in forced vital capacity, a trend also observed in a large population-based cohort study (12). Pulmonary function tests also indicate central airway inflammation in marijuana smokers (6).
To our knowledge, only two previous studies (7,13) have evaluated lung imaging findings in marijuana smokers and neither could establish a clear association between marijuana smoking and emphysema. Other studies investigating this relationship have been case reports and small case series, with little ability to draw clinically relevant conclusions. Other possible lung imaging findings associated with marijuana smoking, such as bronchiectasis, have not been studied.
The purpose of this study was to use chest CT to investigate the effects of marijuana smoking on the lung. We sought to determine if there were identifiable sequelae on chest CT images, including emphysema and signs of airway inflammation.
Materials and Methods
Patients
This retrospective case-control study was performed with approval and waiver of informed consent from the local institutional review board. We included chest CT studies obtained prior to November 2020 at The Ottawa Hospital, a tertiary care center, and its affiliate hospitals. Patients were assigned to one of the following three groups: marijuana smokers, nonsmoker control patients, or tobacco-only smokers.
Marijuana smokers.—Cases were identified by searching for the terms marijuana and cannabis in The Ottawa Hospital picture archiving and communications system, and results were filtered to include only those in which chest CT was performed. Charts were reviewed to assess the frequency and duration of marijuana use, as well as for concomitant tobacco use. A total of 56 marijuana smokers were identified with chest CT performed between October 2005 and July 2020. Patient ages were sorted into 5-year age blocks (15–19 years, 20–24 years, 25–30 years, etc), and the number of men and women in each age category was determined. Marijuana consumption was quantified using the conversion of 0.32 g of marijuana per joint, as described by Ridgeway et al (14).
Nonsmoker control patients.—The pool of control patients was identified by searching for the phrase sarcoma initial staging in The Ottawa Hospital picture archiving and communications system. Initial staging chest CT of patients with newly diagnosed sarcoma and without history of smoking, lung disease, or chemotherapy was chosen. Patient charts were reviewed for use of marijuana or tobacco. In the case of marijuana smokers, the patient was excluded from the nonsmoker control group and added to the marijuana smoker group. New control patients were then selected. If the patient smoked only tobacco, he or she was not included in the nonsmoker control group. Fifty-seven control patients were identified with chest CT performed between April 2010 and October 2019. Control subjects were sorted into 5-year age blocks, and an appropriate age- and sex-matched subgroup was created.
Tobacco-only smokers.—The pool of tobacco-only smokers included patients with a chest CT examination performed as part of the high-risk lung cancer screening program (minimum age, 50 years; smoking history, >25 pack-years). Tobacco-only smokers were selected in a similar manner to those in the nonsmoker control group. Patient charts were reviewed for use of marijuana. If marijuana use was identified, the patient was excluded and added to the group of marijuana smokers, and a new patient was selected. Thirty-three tobacco-only smokers were identified with chest CT performed between April and June 2019.
Age- and sex-matched subgroups.—Because the tobacco smoker group included only patients aged at least 50 years, similarly aged patients in the marijuana smoker group and the nonsmoker control group were included in the subgroup analysis.
Image Analysis
Chest CT studies were obtained with different multidetector scanners with a section thickness of 2 mm or less. Intravenous iopamidol (Isovue; Bracco Imaging) was used in contrast-enhanced studies. The typical volumetric CT dose index and dose-length product for contrast-enhanced studies were 5.7 mGy and 238.5 mGy · cm, respectively. All images from chest CT studies were reviewed separately by two thoracic fellowship-trained radiologists (G.R., P.S.; 10 and 3 years of experience, respectively), who were blinded to clinical history (ie, marijuana and tobacco use) and other imaging findings. To assess interobserver variability, CT images from 30 patients (10 patients from each group) were reviewed initially. Final statistical analyses were performed on imaging findings obtained using consensus reads involving both radiologists on the entire study population of 146 patients. Lung findings assessed were (a) emphysema and (b) airway changes.
Emphysema.—The predominant pattern of emphysema (paraseptal or centrilobular) was recorded in accordance with Fleischner society descriptions (15).
Airway changes.—Bronchiectasis and bronchial wall thickening (Fig 3A) in accordance with descriptions by Ooi et al (16) and mucoid impaction presence or absence were recorded. The presence or absence of inflammatory small airway disease, in the form of centrilobular nodular opacities (15), also was recorded. Air trapping was not assessed because expiratory acquisitions were not available for all patients.
Flowchart shows patient inclusion and exclusion criteria for this study. Subgroups were created by age and sex matching to the tobacco-only cohort (who were taken from the high-risk lung cancer screening program; to qualify for screening, these patients needed to be 50 years or older). Any patients 50 years or older in the marijuana smoker or nonsmoker main groups were included in the subgroup analysis. Patients younger than 50 years in the marijuana smoker or nonsmoker main groups were excluded from subgroup analysis.
Figure 1: Flowchart shows patient inclusion and exclusion criteria for this study. Subgroups were created by age and sex matching to the tobacco-only cohort (who were taken from the high-risk lung cancer screening program; to qualify for screening, these patients needed to be 50 years or older). Any patients 50 years or older in the marijuana smoker or nonsmoker main groups were included in the subgroup analysis. Patients younger than 50 years in the marijuana smoker or nonsmoker main groups were excluded from subgroup analysis.
Download as PowerPointOpen in Image Viewer
Airway changes in a 66-year-old male marijuana and tobacco smoker. Contrast-enhanced (A) axial and (B) coronal CT images show cylindrical bronchiectasis and bronchial wall thickening (arrowheads) in multiple lung lobes bilaterally in a background of paraseptal (arrows) and centrilobular emphysema.
Figure 2: Airway changes in a 66-year-old male marijuana and tobacco smoker. Contrast-enhanced (A) axial and (B) coronal CT images show cylindrical bronchiectasis and bronchial wall thickening (arrowheads) in multiple lung lobes bilaterally in a background of paraseptal (arrows) and centrilobular emphysema.
Download as PowerPointOpen in Image Viewer
Pulmonary emphysema in (A, B) marijuana and (C, D) tobacco smokers. (A) Axial and (B) coronal CT images in a 44-year-old male marijuana smoker show paraseptal emphysema (arrowheads) in bilateral upper lobes. (C) Axial and (D) coronal CT images in a 66-year-old female tobacco smoker with centrilobular emphysema represented by areas of centrilobular lucency (arrowheads).
Figure 3: Pulmonary emphysema in (A, B) marijuana and (C, D) tobacco smokers. (A) Axial and (B) coronal CT images in a 44-year-old male marijuana smoker show paraseptal emphysema (arrowheads) in bilateral upper lobes. (C) Axial and (D) coronal CT images in a 66-year-old female tobacco smoker with centrilobular emphysema represented by areas of centrilobular lucency (arrowheads).
Download as PowerPointOpen in Image Viewer
Non–lung-related findings.—Gynecomastia was recorded with a cutoff dimension of 22 mm of breast tissue (17). Coronary artery calcification was evaluated using the ordinal scoring method previously used by Shemesh et al (18), and a score of 0–12 was recorded for each patient.
Statistical Analyses
Interobserver agreement was evaluated using the Cohen ? statistic. Results were analyzed using ?2 tests to assess for significant differences in rates of emphysema, bronchiectasis, bronchial wall thickening, mucoid impaction, gynecomastia, and coronary artery disease between groups of marijuana smokers, tobacco smokers, and control patients; statistical significance was set at P < .05. Marijuana smokers were compared with control subjects in the main group analysis, and they were compared with both tobacco smokers and control patients in the subgroup analysis. The ?2 tests were performed using an online statistics calculator (https://www.socscistatistics.com/).
Results
Patient Characteristics
A total of 56 marijuana smokers (mean age, 49 years ± 14 [SD]; 34 male, 22 female) and 57 control patients (mean age, 49 years ± 14; 32 male, 25 female) were identified. Patients older than 50 years were included in subgroups for comparison with those who only smoked tobacco; subgroups consisted of 30 marijuana smokers (mean age, 60 years ± 6; 23 male, seven female), 29 control patients (mean age, 61 years ± 6; 17 male, 12 female), and 33 tobacco-only smokers (mean age, 60 years ± 6; 18 male, 15 female). Patient selection criteria are summarized in Figure 1, and patient characteristics are summarized in Table 1.
Table 1: Patient Characteristics
Table 1:
Our ability to quantify marijuana use was limited, with a daily amount specified in only 28 of 56 patients; average marijuana consumption among these patients was 1.85 g per day (range, 0.25–9.25 g per day). There were 50 of 56 marijuana-smokers who also smoked tobacco, with pack-year data specified in only 47 patients; average smoking history was 25 pack-years (range, 0–100 pack-years) (14).
For tobacco-only smokers, average smoking history was 40 pack-years (range, 25–105 pack-years).
Interobserver Agreement
For the analysis of 30 patients, interobserver agreement between the two readers was fair for assessment of bronchiectasis (? = 0.27), moderate for assessment of bronchial wall thickening (? = 0.49), substantial for assessment of emphysema (? = 0.79), and strong for assessment of mucoid impaction (? = 0.84).
Marijuana Smokers versus Nonsmoker Controls
There were differences in rates of emphysema (both paraseptal and centrilobular) (75% vs 5%, P < .001), bronchial thickening (64% vs 11%, P < .001), bronchiectasis (23% vs 4%, P = .002), and mucoid impaction (46% vs 2%, P < .001) between marijuana smokers and nonsmoker control patients, respectively. No patient had pneumothorax.
Subgroup analysis demonstrated differences in frequency of bronchial thickening (83% vs 21%, P < .001), bronchiectasis (33% vs 7%, P = .012) and mucoid impaction (67% vs 3%, P < .001) between marijuana smokers and nonsmoker control patients, respectively.
Centrilobular nodules were observed in 18% of marijuana smokers while no nonsmoker control patients exhibited this finding (P < .001). Gynecomastia was significantly more common in marijuana smokers than in nonsmoker control patients (38% vs 16%, P = .04). While there was a difference in coronary artery calcification rates between marijuana smokers and nonsmoker control patients (43% vs 26%,), this did not reach statistical significance (P = .06).
Marijuana Smokers versus Tobacco-only Smokers
Differences in bronchial thickening (64% vs 42%, P = .04), bronchiectasis (23% vs 6%, P = .04), and mucoid impaction (46% vs 15%, P = .003) were seen in the non–age-matched marijuana group compared with the tobacco-only group. Subgroup analysis again demonstrated significant differences in rates of bronchial thickening (83% vs 42%, P < .001), bronchiectasis (33% vs 6%, P = .006), and mucoid impaction (67% vs 15%, P < .001) in marijuana smokers compared with tobacco-only smokers. Figure 2 demonstrates CT findings of airway changes in a combined marijuana and tobacco smoker. Variable interobserver agreement limits our ability to draw strong conclusions about bronchial wall thickening and bronchiectasis.
We found no difference between the overall rates of emphysema (including both paraseptal and centrilobular emphysema) when comparing non–age-matched marijuana smokers and tobacco-only smokers (75% vs 67%, P = .40); however, higher rates of emphysema were noted when the age-matched marijuana group was compared with the tobacco-only group (93% vs 67%, P = .01). Also, a significant difference in a paraseptal predominant pattern of emphysema was seen in the marijuana smokers compared with the tobacco-only smokers (57% vs 24%, P = .009) (Fig 3), while we found no evidence of a difference in the proportion of those with a centrilobular pattern (37% vs 39%, P = .82). Rates of the key CT findings in each cohort are summarized for the main group in Table 2 and for the subgroup in Table 3.
Table 2: Rates of Thoracic CT Findings among Marijuana Smokers, Nonsmoker Control Patients, and Tobacco Smokers (Main Groups)
Table 2:
Table 3: Rates of Thoracic CT Findings among Marijuana Smokers, Nonsmoker Control Patients, and Tobacco Smokers (Age- and Sex-matched Subgroups)
Table 3:
Discussion
In this era of legalization and increasing consumption of marijuana, we sought to identify the imaging features of marijuana smoking on chest CT scans. We found higher rates of emphysema among marijuana smokers (42 of 56, 75%) than among nonsmokers (three of 57, 5%) (P < .001) and among age-matched marijuana smokers (28 of 30, 93%) than among tobacco-only smokers (22 of 33, 67%) (P = .009). Paraseptal emphysema was more predominant in marijuana smokers (27 of 56, 48%) than in tobacco-only smokers (eight of 33, 24%) (P = .03) and in age-matched marijuana smokers (17 of 30, 57%) than in tobacco-only smokers (eight of 33, 24%) (P = .009). Markers of airway inflammation were higher among marijuana smokers than among other groups for both non–age-matched and age-matched subgroup comparisons (P < .001 to P = .04). Gynecomastia was more common in marijuana smokers (13 of 34, 38%) than in control patients (five of 32, 16%) (P = .039) or tobacco-only smokers (two of 18, 11%) (P = .04). There was no evident difference in the presence of coronary artery calcification between age-matched marijuana smokers (21 of 30, 70%) and tobacco-only smokers (28 of 33, 85%) (P = .16).
It has been posited that certain maneuvers performed by marijuana smokers, such as full inhalation with a sustained Valsalva maneuver, may lead to microbarotrauma and peripheral airspace changes, such as apical bullae. In our study, paraseptal emphysema was the predominant pattern seen in marijuana smokers, while centrilobular emphysema was the predominant pattern seen in tobacco-only smokers. This may represent an earlier stage of apical bulla formation reported in marijuana smokers (19,20) and may explain the absence of the typical pulmonary function test changes of chronic obstructive pulmonary disease in marijuana smokers. The ?2 tests revealed similar overall rates of emphysema in the non–age-matched marijuana smoker group and the tobacco-only smoker groups and higher rates of emphysema among age-matched marijuana smokers compared with tobacco-only smokers. This is in contradistinction to a study by Ruppert et al (21), which showed similar prevalence of emphysema among 38 tobacco-only smokers and 32 tobacco and marijuana smokers but occurrence of emphysema in the latter group at a younger age. We were not able to establish a definite association between marijuana smoking and emphysema or bullous disease. Causality needs to be further examined in larger patient cohorts with prospective accurate quantification data, given the increasing body of evidence suggesting an association between smoking marijuana and spontaneous pneumothorax (22,23).
Bronchiectasis, bronchial wall thickening, and mucoid impaction are CT indicators of airway inflammation. Our findings suggest that smoking marijuana leads to chronic bronchitis in addition to the airway changes associated with smoking tobacco. This is especially striking given the extensive smoking history of patients in the tobacco-only group (smoking history, 25–100 pack-years). In addition, our results were still significant when comparing the non–age-matched groups, including younger patients who smoked marijuana and who presumably had less lifetime exposure to cigarette smoke. Further studies in larger cohorts are needed to better define imaging correlates of airway inflammation and chronic bronchitis that have been described in association with marijuana smoking in previous clinical studies and systematic literature reviews (2,24).
Poorly defined centrilobular ground-glass nodules can denote inflammatory small airway disease corresponding to the entity of respiratory bronchiolitis characterized by accumulation of pigmented histiocytes adjacent to respiratory bronchioles and alveolar ducts and sacs. This finding is commonly related to cigarette smoking (25,26) but can be related to inhalation of a variety of toxic particles (15). A histopathologic study comparing 10 marijuana smokers with five tobacco smokers and five nonsmokers reported that marijuana smoking was associated with massive intra-alveolar accumulation of pigmented histiocytes evenly throughout the pulmonary parenchyma, assumed to be related to higher particulate matter concentration and deeper and longer inhalation techniques used by marijuana smokers (27). In our study, we found no differences in the occurrence of centrilobular nodules between marijuana smokers and tobacco-only smokers. However, this may be because 89% (50 of 56) marijuana smokers were also tobacco smokers. Further assessment in imaging-based studies with larger patient cohorts and better quantification data are required. Furthermore, biopsy confirmation may be needed to better understand the histopathology of these nodules in marijuana smokers: Are they related to respiratory bronchiolitis or organizing pneumonia (described by Berkowitz et al [28]).
We were unable to confirm an association between coronary artery calcification and marijuana smoking, similar to a systematic review of 24 articles that reported that evidence on the association of marijuana use with cardiovascular risk factors is insufficient to make conclusions (29). At least one recent study of 146 young marijuana users with chest pain found that marijuana use did not confer additional risk of coronary artery disease, as detected with coronary CT angiography (30). Tobacco smoking, on the other hand, is an established risk factor for coronary artery disease (31). Our study also enabled us to confirm the well-known relationship between regular long-term marijuana use and gynecomastia (32).
Our study had limitations. First, the small sample size precluded us from drawing strong conclusions. Second, the retrospective nature of the study had its own inherent limitations. Third, there was inconsistent quantification of patient marijuana use, due in part to the previous illegal nature of marijuana possession, which led to a lack of patient reporting. Accurate quantification is further complicated by the fact that users often share joints, use different inhalation techniques, and use marijuana of varying potency. Fourth, given that most marijuana smokers also smoke tobacco, the synergistic effects of these two substances cannot be effectively evaluated. Fifth, only a portion of patients could be age matched, since the tobacco-only cohort was taken from the lung cancer screening study and the patients were aged at least 50 years. Due to the age mismatch in the larger cohort, there are differences in the duration of smoking. Lastly, variable interobserver agreement limits our ability to draw strong conclusions about bronchial wall thickening and bronchiectasis.
In conclusion, our study suggests that distinct radiologic findings in the lung may be seen in marijuana smokers, including higher rates of paraseptal emphysema and airway inflammatory changes, such as bronchiectasis, bronchial wall thickening, and mucoid impaction when compared with nonsmoker control patients and those who only smoke tobacco. These findings may be related to specific inhalational techniques while smoking marijuana, as well as to the bronchodilatory and immunomodulatory properties of its components. Further larger and prospective studies are necessary to confirm and further elucidate these findings, as marijuana use is bound to increase in the future, given the increasing legalization of its use for medical and recreational purposes.
New York Cannabis Farms Have $750 Million of Weed — and Nowhere to Sell It
Growers in upstate New York are figuring out how to keep a glut of weed fresh as the state stalls on retail licenses.
Bonno
18 novembre 2022 à 06:00 UTC-5
By almost all metrics, New York’s cannabis market rollout should be in the final innings. The state began handing out growing licenses to more than 200 farms last spring and farmers have since sowed seeds, tended to rows of plants all summer, and just in the last few weeks, finished harvesting. Now, hundreds of thousands of pounds of weed — worth hundreds of millions of dollars — is ready to be sold at dispensaries.
There’s one hitch: Instead of being shipped to retail stores, the weed is just piling up. Though a rampant gray market is already up and running, not one legal recreational dispensary has yet opened in New York, despite the state regulator’s repeated assurances that cannabis stores would be a fixture by the end of this year.
The languishing stockpiles — estimated to weigh around 300,000 pounds, according to the Office of Cannabis Management — pose a host of problems for farmers, not least of which is that over time, cannabis can deteriorate fast. Based on an average estimated wholesale value of about $2,500 per pound, according to Cannabis Benchmarks, a research firm that tracks wholesale marijuana prices nationwide, the hoard could be worth as much as $750 million. If farmers don’t get their harvest into stores soon, that near-billion-dollar revenue will eventually start to dwindle. In the meantime, farmers have to figure out how to store it indefinitely, making sure the weed is as fresh as possible while also keeping it safe from theft or potential contamination.
Applicants for one of the initial 150 individual retail licenses and 25 nonprofit licenses expect to hear back from the state any day, but a green light from the OCM is only the beginning of the long process involved in opening a storefront.
“It’s an unclear path to market,” said Melany Dobson, chief executive officer of Hudson Cannabis, a 520-acre farm about two hours north of New York City. “We’ve been told again and again that dispensaries will open before the end of the year. I’ve acted as though that’s our single source of proof, so we’re prepared for that.
Dobson has been running the operations, formerly known as Hudson Hemp, alongside her brother Ben Dobson, and sister Freya Dobson, since 2016. On a bright day in early November, the fields lay bare, with wisps of withering vegetation strewn about. Harvest had wrapped up the previous week and the heaps of cannabis were elsewhere, in a secure location.
Hudson Cannabis has the resources to do this: It’s owned by David Rockefeller’s daughter, Abby Rockefeller, and has been preparing for the transition to growing legal cannabis for years. Until recently, the project had been cultivating hemp — identical to cannabis, just with less than 0.3% of tetrahydrocannabinol — but now is almost solely focused on THC-rich cannabis varieties, with its first season consisting of 14 strains, ranging from “Dosidos” to “Sour Glue.”
Melany’s original financial model showed that revenue would start to stream in around November. “Which is this month,” she said, laughing. “So that’s clearly not the case.”
The OCM, which oversees cannabis licenses from its base in Albany, has set a high bar for its first round of retail proprietors — and given itself a mound of paperwork to wade through in the process. The state has promised the first licenses will go to applicants who were convicted of marijuana-related offenses before recreational pot was legalized, or their relatives, as long as they have experience owning and operating a business in New York. A lot of documentation is required to prove those credentials, along with a non-refundable $2,000 application fee.
Last Thursday, a federal judge in Albany temporarily blocked the OCM from issuing retail licenses in a handful of regions, including Brooklyn, after a lawsuit complained of overly stringent requirements.
“The goal is to open dispensaries by the end of this year,” said Aaron Ghitelman, a spokesperson for OCM. “We’re still gunning to get the first sales on board” by 2023.
The regulator had similar priorities in mind when it handed out cultivation licenses, giving them to smaller operations that had already been growing hemp — often used in legal CBD products — over big corporations with no experience in the state. The permits came with a long list of conditions, including that farms only grow one acre of so-called canopy (equivalent to about two acres of land area) and that the majority of the growing occurs outdoors.
That keeps New York’s farmers on a tight schedule, constrained by the typical Northeast climate. Farmers usually first plant the cannabis seeds in May to allow for it to be sun grown, as opposed to in greenhouses. The busy season is crammed between then and late October when harvest starts. For the rest of the year — or however long it takes for stores to be ready to place orders — the challenge is, literally, keeping the weed green.
Much like wine, cannabis needs to be kept in a temperature and humidity-controlled environment. During the drying process, for instance, the plants need to be kept at a precise temperature. Changes in the crop’s potency and smell are the biggest concerns for farmers over time, but it also changes visually.
“Old cannabis starts to have a brownish glow,” Melany said. If exposed to air, light and warmer temperatures for long enough, THC will eventually break down to another compound known as cannabinol, which is weaker, and ultimately, less valuable.
Hudson Cannabis claims it has the facilities to store harvested cannabis in conditions that limit degradation for as long as 12 months — an expensive set-up that not every grower has the resources to replicate. Dozens of stacked black and yellow bins already line the company’s storage facility, with each one holding about five pounds of the plant. Even so, the farmers are adapting their operation to account for delays.
“We’re not packaging or processing flower yet,” Melany said, referring to the raw portion of the plant that can be wielded into products, like dried, smokable cannabis. “We’re trying to retain as much quality as possible. And rushing it into the finished product bags is not the way to do that.”
When the storage facility’s doors are closed, it looks like any other agricultural warehouse. But when they’re opened, the telltale smell of the cannabis plant rushes out, posing yet another problem for the farmers: security.
All of the 261 cultivators granted a conditional license had to submit a security plan along with their application to the state. But there was little guidance as to what it should look like, and the plans were largely left up to the farmers’ discretion.
“We have an all-night in-person security presence,” said Ben Dobson, co-founder of Hudson Cannabis. “As a modern hippie I’m not in love with that. We’re trying to make it look good. We didn’t do the chain-link fence, we did the eight-foot tall deer fence. But it sucks.” So far, they’ve paid around $100,000 for a security system, but are gearing up to spend an additional $250,000 soon.
For Mario Rodriguez, who runs a private security firm based in Buffalo that has pushed into the cannabis industry, it means business has been booming in recent months. Forseti Protection Group, of which he’s president, focuses on the technology side of security, including services like infrared scanners that can be installed on a farm’s perimeter to detect trespassers. He says inquiries from potential clients have increased more than 10-fold in the past three months alone.
“They don’t know how much of their product is actually going to be rolled out,” said Rodriguez. “We’re just operating under the assumption that everything has to be safe and ready.”
Not every farm is like Hudson Cannabis, with its access to deep pockets and a combined decade’s worth of experience between Melany and Ben alone. The company also leases out swaths of land to nearby farmers to graze grass-fed beef and goats. The Dobsons are optimistic that they’ll be able to ride out the rocky period between harvest time and the first ground-breaking for retail dispensaries.
For many of the other farms across New York state, the stakes are higher. A glut of hemp-derived CBD products in recent years triggered a nationwide plummet in wholesale prices, leaving some growers in financial disarray or bankruptcy. Legal THC sales looked like a promising way for such farms to recoup their losses: The market for adult-use cannabis is projected to reach $1.3 billion in sales in New York City alone by next year, according to a statement in August from the mayor’s office. That $1.3 billion is largely owned by legacy.
Until those shops open up, farmers like the Dobsons are in a bind. Selling across state lines isn’t allowed, so growers don’t have the option to offload their crops to dispensaries in Massachusetts, New Jersey or states further afield that already have retail operations up and running. It’s New York or nowhere.
“We’re ready to launch a full suite of products into the New York market,” Ben said. “We’re spending money with no end in sight until the state gets its act together on retail.”
Doomed.
Busting the competition?
Back to square one??
Let,s see how that works for that stock market bunk.
They should "try" to grow better weed for pennies.
Doomed.
New York law enforcement swoops down on gray market cannabis shops
https://www.marketwatch.com/story/new-york-law-enforcement-swoops-down-on-gray-market-cannabis-shops-2022-11-18
Industrial Hemp Market worth $18.1 billion by 2027 - Exclusive Report
https://420intel.com/articles/2022/11/18/industrial-hemp-market-worth-181-billion-2027-exclusive-report
Marijuana cultivation to lead Alaskan job growth over next decade
https://alaskapublic.org/2022/11/17/marijuana-cultivation-to-lead-alaskan-job-growth-over-next-decade/
Canadians have lost more than $131 billion investing in cannabis companies:
Tell us how much have you lost with CGC ?
Don't tell me that you are in the Black because stock price hasn't been this low since the first few months
Canadians who invested in cannabis companies have lost more than $131 billion, according to data collected by law firm Miller Thomson, which calculated the total losses of 183 publicly traded and licenced cannabis producers.
It’s a staggering number that if broken down per capita would equate to each Canadian citizen losing about $43,000.
Larry Ellis, a lawyer with the firm, points out to CTV National News that he “doesn’t know of many Canadian investors who can afford to lose $40,000 individually.”
From high times to large swaths of an industry now going up in smoke, the money lost is just one example of the current state of the Canadian cannabis industry. Many are now pointing the finger at the federal government's rollout of legalization, while noting that the black market is thriving.
https://www.ctvnews.ca/canada/canadians-have-lost-more-than-131-billion-investing-in-cannabis-companies-firm-1.6156722
Germany’s plan to legalize recreational marijuana hits potential hurdle
Bonno
November 17, 2022
SHARE
The health minister of Germany’s largest state is asking a key European Union official to block Germany’s plan to regulate recreational marijuana production and sales.
Bavaria’s health minister, Klaus Holetschek, met in Brussels this week with Monique Pariat, the EU’s director-general for migration and home affairs, to make the request, according to the Associated Press.
Holetschek is a member of the center-right Union bloc, an opposition party.
According to the AP, Holetschek strongly opposes the blueprint by German Chancellor Olaf Scholz to legalize cannabis in Europe’s largest economy.
In October, the German government published key details of its plan to legalize and regulate recreational cannabis, including what Health Minister Karl Lauterbach described as “complete” cultivation within the country.
Some international businesses had been hoping Germany would allow imports, possibly from other European Union countries, even though that would breach international drug-control treaties.
As part of that outline, Germany’s blueprint of the law is being sent to the European Commission, the EU’s executive branch, for approval to ensure it is compatible with EU and global drug laws.
Germany’s government said the legislative process, including actually drafting a law, will continue only if the plan is approved by the EU.
According to the AP, Holetschek told the EU’s Pariat that “the German government’s planned cannabis legalization doesn’t just endanger health, but I am convinced that it also violates European law.”
If approved by the European Commission, and then ultimately by German lawmakers, the blueprint could serve as a basis for broader cannabis reform in countries across the European Union seeking to follow Germany’s example.
Home / Legal
GOP congressman compares marijuana industry to ‘slavery’
Bonno
November 17, 2022
SHARE
A Republican congressman notorious for blocking federal marijuana reform nearly derailed a “historic” Capitol Hill hearing on federal legalization Tuesday when he compared the MJ industry to slavery, comments other lawmakers decried as “offensive.”
During a House of Representatives subcommittee hearing in which lawmakers from both major parties mostly extolled legalization and called for federal reform, U.S. Rep. Pete Sessions, R-Texas, – who regularly blocked marijuana reform bills as chair of the House Rules committee from 2013 to 2019 – also offered a preview of the anti-legalization arguments likely to be heard during the next Congress and in statehouses across the country.
Sessions connected legalization to traffic fatalities and high-THC products to health problems, and studies examining both were introduced into the record.
But Sessions drew bipartisan criticism for a “patently offensive” comment in which he drew an analogy between the industry and slavery.
“The product is being marketed,” he said. “The product is being sold. The product has been advocated by people who were in it to make money.”
“Slavery made money also and was a terrible circumstance that this country and the world went through for many, many years.”
Sessions’ statement was disavowed by other lawmakers on the committee, who apologized for the “peculiar analogy.”
The Texas Republican also earned criticism from other witnesses giving testimony at the hearing, including the mayor of Birmingham, Alabama, Randall Woodfin, who is Black.
“Words matter,” Woodfin said, according to the Birmingham Times.
“While I’m on record, I would just like to say to you directly, your committee members, that putting cannabis and slavery in the same category is patently offensive and flagrant.”
Looks like "legalization will have to wait.
No reason to be more valuable than potatoes.
It,s artificial and it cannot survive.
Prices are dropping monthly as lpes are overgrown.
Doomed!!!
Marijuana Is A More Valuable Crop Than Potatoes Or Rice, New Leafly Report On Adult-Use Market Finds
https://www.marijuanamoment.net/marijuana-is-a-more-valuable-crop-than-potatoes-or-rice-new-leafly-report-on-adult-use-market-finds/
Senate Sends Marijuana Research Bill To Biden’s Desk, With Schumer Saying He’s Having ‘Productive Talks’ On Broader Reform
https://www.marijuanamoment.net/senate-lifts-hold-on-house-passed-marijuana-research-bill-with-expedited-vote-expected-soon/
GOP Congresswoman Discusses Plans To Advance ‘Winning’ Marijuana Issue Under New House Majority
https://www.marijuanamoment.net/gop-congresswoman-discusses-plans-to-advance-winning-marijuana-issue-under-new-house-majority/
Senate Lifts Hold On House-Passed Marijuana Research Bill, With Expedited Vote Expected Soon
https://www.marijuanamoment.net/senate-lifts-hold-on-house-passed-marijuana-research-bill-with-expedited-vote-expected-soon/
The Next Wave of Cannabis Marketing and Advertising
https://www.rollingstone.com/culture-council/articles/next-wave-of-cannabis-marketing-and-advertising-1234631114/
Maryland Lawmakers’ Marijuana Workgroup Discusses Tax Options In First Meeting Since Voters Approved Legalization On Ballot
https://www.marijuanamoment.net/maryland-lawmakers-marijuana-workgroup-discusses-tax-options-in-first-meeting-since-voters-approved-legalization-on-ballot/
Kansas Dems. remain committed to passage of medical marijuana legislation
https://www.wibw.com/2022/11/16/kansas-dems-remain-committed-passage-medical-marijuana-legislation/
Kentucky Governor Signs Executive Order To Allow Use of Medical Cannabis
https://hightimes.com/news/kentucky-governor-signs-executive-order-to-allow-use-of-medical-cannabis/
And when the US turns on refer, share prices will jump.
Until folks realize the market was allready oversaturated...lol
Cannabis prices will drop and drop until they pop.
You,ll be back to square one, i.e. : RED
Legacy market has been around too long.
THEY OWN THIS MARKET!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
They,ve got it down capitalist style and make a good living.
Add to the mix many passionate folks like Awesomesound and bonito who take immense pleasure at overgrowing the refer madness government.
Stock market weed growers are doomed!
Home / News by State / California
Small Humboldt County cannabis farmers go direct to consumers
November 14, 2022
Bonno
Hear from Berner (Cookies), Nancy Whiteman (Wana Brands), Sandra Bergman (Schwazze) and other top cannabis industry leaders and learn their strategies for establishing a successful cannabis brand at MJBizConLegacy in Las Vegas (Nov. 15-18).
Efforts by small cannabis farmers in California’s famed Emerald Triangle to reach consumers directly is gaining traction in the market.
Humboldt Family Farms on Monday announced the launch of a line of hand-curated, sun-grown marijuana products from legacy craft farmers in Humboldt County available through home delivery.
“Our network of dedicated farmers has made a huge impact on this fast-growing category over generations,” Scott Vasterling, founder of Humboldt Family Farms, said in a news release.
The line of premium flower, vape cartridges and pre-rolls highlight specific cannabinoids and terpene profiles for each product.
Appellation programs, farming cooperatives and co-branding partnerships between growers and distributors have helped some legacy farmers in Humboldt, Mendocino and Trinity counties build their brands and businesses amid a challenging economic environment in California.
Over the past few years, California marijuana cultivators have been stung on a variety of fronts, including depressed wholesale prices, rising costs, severe drought, business failures and a continued lack of retail access across wide swaths of the state.
In response, several farmers have told MJBizDaily they’ve had to fallow their land, or not grow crops, while others have chosen to let their licenses expire.
Weed Consumption District Along Missouri River Coming to Kansas City Suburb
https://hightimes.com/news/weed-consumption-district-along-missouri-river-coming-to-kansas-city-suburb/
Weed Consumption District Along Missouri River Coming to Kansas City Suburb
https://hightimes.com/news/weed-consumption-district-along-missouri-river-coming-to-kansas-city-suburb/
Legal marijuana boosters look ahead to Oklahoma, Ohio and beyond
https://fortune.com/2022/11/14/where-is-marijuana-legal-midterm-elections-missouri-maryland-ohio-oklahoma/
They pass go but can,t collect.
Growing bunk = no money to be made.
North America cannabis market is flooded.
Nowhere to go but down.
The black market strangled California's legal weed industry. Now it's coming for New York.
Lax enforcement has allowed illicit sales to flourish — with little incentive to go mainstream.
A vendor sells marijuana.
New York legalized adult-use marijuana more than a year ago but is yet to issue a single dispensary license. The result has been a weed free-for-all. | Richard Vogel/AP Photo
NEW YORK — Inside a Brooklyn smoke shop, past rows of bongs and other paraphernalia, a display case is piled high with legal hemp and CBD — but a store employee has some advice.
“That’s not the stuff you want,” he confides to a reporter who had been wordlessly eyeing the display.
Unprompted, the worker reaches behind the counter — but not before idly musing, “you look like a cop” — and produces a plastic shopping bag containing what he says are genuine marijuana gummies, imported from California.
“I can sell you mushrooms, too,” he adds.
It’s become a familiar scene in New York City. The state legalized adult-use marijuana more than a year ago but is yet to issue a single dispensary license. The result has been a weed free-for-all: Cannabis seems to be for sale everywhere — head shops, bodegas, even from folding tables on street corners. Some dealers brazenly sell in public, and many boast their products were grown in California.
The outcome is not unlike what happened when California legalized marijuana. Six years later, illegal sellers and growers continue to thrive there. Despite those struggles, New York leaders decided to take a gentle approach with anyone selling without a license. Now, an industry expected to generate more than 20,000 new jobs and a $4.2 billion market by 2027 could stumble on arrival as it competes with the booming black market.
Already, some legitimate companies that were planning major investments are heading for the hills.
“Everybody seems to be selling cannabis, and until there’s enforcement, there’s really no concern of a penalty.”
Owen Martinetti, Cannabis Association of New York
“Everybody seems to be selling cannabis, and until there’s enforcement, there’s really no concern of a penalty,” said Owen Martinetti of the Cannabis Association of New York, who is personally calling for stronger civil enforcement. “If there’s already competition and it’s not enforced, it kinda begs the question, are [the regulated stores] really set up for success?”
Blindsided
When New York became the 15th state to legalize cannabis last year, lawmakers saw an opportunity to reverse past wrongs. They expunged certain marijuana-related criminal records and offered priority on marijuana business licenses to “justice-involved people” with prior weed convictions.
Against that backdrop, lawmakers hesitated to throw the book at those now caught selling cannabis without a license and gave hazy enforcement instructions to the state’s Office of Cannabis Management.
“Since we didn’t think this was going to happen, we didn’t put anything in the bill that gave OCM and the police departments very clear-cut rules of the road to close them down,” said state Sen. Liz Krueger, a sponsor of the bill to legalize recreational cannabis.
Krueger believes police already have the right to seize illegal products and shutter offending shops. New York Mayor Eric Adams, a fellow Democrat, didn’t appear to share that viewpoint, however.
Mayor Eric Adams speaks.
“A police officer can’t just walk in and conduct an apprehension, or an arrest, or confiscate the item — there’s a process,” New York Mayor Eric Adams, a former police officer, said. | Brittainy Newman/AP Photo
“A police officer can’t just walk in and conduct an apprehension, or an arrest, or confiscate the item — there’s a process,” he said last month. Adams, a retired police captain, urged New Yorkers to notify police about illegal shops and said he plans to lobby the state Legislature in January for greater clarity on what the NYPD and New York City Sheriff’s Office can do.
City Hall spokesperson Kayla Mamelak said Adams has clearly articulated that illegal businesses will not be tolerated.
“Multiple agencies — on both the city and state level — are coordinating closely to ensure compliance and equity in the emerging cannabis market,” she said in a statement. “The New York City Department of Finance’s Sheriff’s Office has conducted hundreds of business inspections so far this year to ensure compliance with all applicable laws. During the course of such inspections, thousands of products deemed to be contraband have been seized and criminal and civil penalties have been imposed when appropriate. We will continue to work collaboratively with all our partners to ensure compliance with all laws affecting the public safety of New Yorkers.”
Earlier this year, a bill stalled in Albany that would have strengthened penalties for illicit cannabis sales and clarified the OCM’s role in enforcement. Some lawmakers were concerned that the measure established new criminal penalties.
Many stores selling unregulated cannabis products are already licensed to sell alcohol, tobacco and lottery tickets. Governments could revoke offending stores’ licenses,” said Assembly Majority Leader Crystal Peoples-Stokes, but “we have not sought to do that at all.”
In August, Adams confiscated 19 trucks that were illegally selling cannabis. The alleged violation: Selling edibles and other food products without proper city Health Department permits.
Some smaller municipalities in other parts of the state have shut down stores, and the cannabis management office sent cease-and-desist letters to 52 retailers statewide earlier this year.
‘Set up to fail’
But the recent enforcement push may not be enough to blunt the illegal market’s impact, especially with the first regulated stores planned to open in the coming months.
“I think we’re already approaching the point of no return,” said an executive at a medical and adult-use cannabis company with operations in New York who requested their name be withheld because regulatory negotiations are ongoing. If lawmakers don’t contain the issue by next year, “the first set of dispensaries will have been set up to fail, and the state will either have to spend money bailing them out or we will see people turning in their licenses.”
In a statement, OCM spokesperson Aaron Ghitelman said the agency has maintained “an open line of communications with law enforcement and other government entities across the state” since it was created, adding it was committed to investigating and shutting down unlicensed shops.
“From the Town of Cheektowaga to the City of New York, OCM and law enforcement agencies have effectively stopped illicit activity throughout the state,” he said. “This activity has included the seizure of products, the issuance of cease-and-desist letters, and removal of trucks used for the illicit sale of cannabis. … These illicit shops undermine our Office’s mission, and the equitable market we’re building, and we will continue to enforce the laws on the books to end their operations.”
Further complicating matters, New York consumers have become accustomed to the illicit market, and the state needs to persuade them to switch over to regulated weed if it wants the legal industry to succeed.
Illicit shops can sell at significantly lower prices. They don’t pay taxes and licensing fees, and their wares are often sourced from states with cheaper production costs.
“Speaking as just one sponsor of the original bill, I am totally open to reevaluating how we tax, what formulas we use and how we calculate it” if current rates prove overly burdensome to legal operators, Krueger said.
The California-New York cannabis pipeline is “very old and very well established,” according to Amanda Reiman, chief knowledge officer at cannabis intelligence company New Frontier Data.
California’s black market undermined its own legal industry. Six years out from the state’s vote to legalize recreational marijuana, illegal sales have far outpaced the regulated market, and many operators have closed up shop. High taxes, local government opposition and competition from the underground market have stifled the success of the legal cannabis industry in the nation’s most populous state.
“We have not been successful in California getting people to adopt the regulated market in any large way.”
Amanda Reiman, chief knowledge officer at cannabis intelligence company New Frontier Data.
“We have not been successful in California getting people to adopt the regulated market in any large way,” Reiman said.
New York may experience a honeymoon period as the novelty of legal dispensaries pulls in consumers. But industry members worry long-term success will falter.
Time running out
The sooner legal dispensaries are established, the easier it will be to shut down unlicensed businesses, according to Peoples-Stokes, who added that she has “no desire to criminalize people for products that we made legal and didn’t put regulations in place.”
Meanwhile, New York has lost major cannabis investments. In August, Ascend Wellness scrapped a $73 million bid to acquire a New York company’s medical licenses, citing, among other issues, concerns over the state’s establishment of the recreational market and insufficient policing of the illicit market.
“It’s eroding trust, not only from investors, but also [longtime illegal] operators” who the state should be encouraging to go mainstream, the industry insider said. “They’re not sure that the state is going to help them succeed if they make that transition.”
If the industry sours, legal operators are “going to be putting a lot of pressure — politically and otherwise — on politicians,” said Robert DiPisa, co-chair of the Cannabis Law Group at law firm Cole Schotz P.C.
“If you’re not going to play by the rules, there has to be some sort of penalty,” Martinetti said. “If we’re going to spend money on a license and pay taxes and invest money and build these businesses, then there has to be a pull — there has to be a reason … and that’s got to be the concern of being challenged by the state.”
Minnesota health officials weigh whether to allow medical cannabis for opioid use disorder
https://www.minnpost.com/mental-health-addiction/2022/11/minnesota-health-officials-weigh-whether-to-allow-medical-cannabis-for-opioid-use-disorder/
Medical Marijuana business in Texas steadily growing
https://www.420intel.com/articles/2022/11/14/medical-marijuana-business-texas-steadily-growing
Cannabis Ballot Results No Cause For Consternation
https://www.jdsupra.com/legalnews/cannabis-ballot-results-no-cause-for-7590579/
While some are disappointed that only two of the five state cannabis legalization ballot initiatives passed, I see the results as extremely positive.
I recall the fleeting exhilaration of watching 2016 election returns on state cannabis legalization ballot initiatives, which passed in eight of nine states. Back then, I was watching television and reporting those results to clients. This year, with only two of the five adult use legalization ballot initiatives passing, some in the press and industry were quick to ask whether “cannabis has hit a wall.” That, from my perspective, is an ahistorical and out of context view for several reasons.
Passing cannabis legal reform has been challenging in every state over the last two decades. Yet, continuing the steady pace, the twentieth and twenty-first states – Maryland and Missouri – passed adult use cannabis legalization. Now, half of the US population lives in states that have legalized the sale of cannabis to adults.
Those are the two most populous of the five states with ballot initiatives in this election cycle. Together they have over 12 million people, in contrast to the states were the initiatives did not pass – Arkansas, North Dakota, and South Dakota – with total populations under 5 million. Oklahoma, in the middle of that population range with approximately 4 million people, will vote on cannabis legalization next spring.
Those states voting on cannabis legalization demonstrates continued progress. “Red” states like Missouri even voting for, needless to say passing, full legalization seemed unimaginable just a few years ago, as did Alabama, Mississippi, and South Dakota legalizing medical cannabis.
We are now reaching for the “highest hanging fruit.” That needs to be done in the right way and at the right time. Many viewed the Arkansas initiative as flawed, for example. In addition, we were reaching for the high fruit in a midterm election under a relatively unpopular president. That dynamic usually generates higher turnout for the opposing party, which in this case is the side that more traditionally votes against cannabis reform.
The relative good news was not limited to the ballot initiatives. Democrats holding the governor’s office in Pennsylvania and Wisconsin, for example, will likely be important for future legalization efforts. With demand for cannabis and cannabis products and support of legalization remaining robust, a few ballot initiative failures do not represent the reform movement hitting a wall. There are certainly challenges and risks, but these results are not a cause for consternation.
After election, marijuana advocates look to next states
https://www.thestate.com/news/article268726187.html
Medical Cannabis Use by Rheumatology Patients According to Inflammatory versus Non-Inflammatory Condition
kevin boehnke1, Tristin Smith1, Ying He1, Bonno, marc martel2, david williams1 and Mary-Ann Fitzcharles3, 1University of Michigan, Ann Arbor, MI, 2McGill University, Montréal-Ouest, Canada, 3McGill University, Montréal, QC, Canada
Meeting: ACR Convergence 2022
Keywords: pain, Therapy, complementary
Favorite
Share
EmailPrint
SESSION INFORMATION
Date: Saturday, November 12, 2022
Session Title: Abstracts: Exemplary Interprofessional Research
Session Type: Abstract Session
Session Time: 4:30PM-6:00PM
Background/Purpose: Persistent pain and poor sleep are common symptoms experienced by patients with rheumatic diseases. Medical cannabis (MC) may offer symptomatic relief and is increasingly accessible to patients. Recent recreational cannabis legalization in many United State (US) states and Canada has opened this access gateway for patients who may be using MC with physician oversight or by self-administration. Improved understanding of the current MC culture will facilitate empathetic patient centered care. The objective of this survey was to characterize MC use amongst rheumatology patients in the US and Canada and to understand demographic and clinical differences between those with inflammatory versus non inflammatory rheumatic conditions.
Methods: Partnering with the Arthritis Foundation (US) and the Arthritis Society (Canada), we investigated MC use by persons self reporting a rheumatic condition via an online anonymous survey. We categorized 797 survey participants who currently use MC for symptom treatment as having an inflammatory (n=441) or non-inflammatory (n=356) rheumatic condition. Excluded were those under 18, residing outside the US or Canada, not fluent in English or French, without a rheumatic condition, who failed to provide consent or did not complete the survey. Symptom burden was assessed using the 2011 Fibromyalgia diagnostic criteria and the PROMIS Global Health (v1.2) instrument, with physical and mental health scores converted to respective t-scores for analysis. Symptom change was assessed using a 7-point Likert scale ranging from very much worse to very much better. R (version 4.1.1) was used for statistical analyses.
Results: Participants were predominantly white females, with some education beyond high school, and about 1/3 were employed (Table 1). Both groups reported high symptom burden with the inflammatory group reporting higher FM scores (p< 0.0001) and lower PROMIS physical (p< 0.0001) and mental health (p=0.0011) scores despite being younger on average (p< 0.0001) (Table 1). Both groups reported moderate symptom relief across all domains, with greater improvements in joint stiffness and global health for the inflammatory group compared to the non-inflammatory group (Figure 1, p< 0.05). Respondents also reported substantial medication substitution across prescription drug classes related to MC use (Figure 2). Notably, over half of participants who used opioids (51.9%), SNRIs (64.0%), SSRIs (68.0%), gabapentinoids (67.3%), and sleeping pills (69.4%) reported discontinuing these medications entirely as a result of MC substitute. No significant differences were observed between the two groups within any of these prescription medication classes.
Conclusion: High symptom burden is likely a driver for MC use by persons with both inflammatory and non-inflammatory rheumatic conditions. The substantial symptom relief and reported reduction or discontinuation of prescribed symptomatic treatments warrants formal study.
Supporting image 1
Table 1: Demographic and clinical characteristics of medicinal cannabis users by diagnosed condition: Current use classified as individuals who currently use medicinal cannabis to manage pain or other symptoms. Differences between diagnosis group were assessed using Chi-square tests for categorical variables and t-tests for continuous variables. Higher values for FM scores are indicative of more severe fibromyalgia symptoms, whereas higher PROMIS scores demonstrate greater physical and mental health.
Supporting image 2
Supporting image 3
Disclosures: k. boehnke, Tryp therapeutics; T. Smith, None; Y. He, None; m. martel, Sant cannabis; d. williams, Swing therapeutics; M. Fitzcharles, None.
To cite this abstract in AMA style:
boehnke k, Smith T, He Y, martel m, williams d, Fitzcharles M. Medical Cannabis Use by Rheumatology Patients According to Inflammatory versus Non-Inflammatory Condition [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/medical-cannabis-use-by-rheumatology-patients-according-to-inflammatory-versus-non-inflammatory-condition/. Accessed November 13, 2022.
© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY
These greedy should have known better...
2 dudes knew all along that stock market bunk Ponzi was a dud...
Awesomesound & Bonno.
But you prefered to listen to canna naive Linton.
They took you for a spin.
Ontario's licensed cannabis producers losing revenue to blackmarket
https://ottawasun.com/news/local-news/ontarios-licensed-cannabis-producers-losing-revenue-to-blackmarket
Health Canada wants to end medical cannabismedicinal
HEALTH CANADA WANTS TO END MEDICAL CANNABIS
CALEB MCMILLAN·NOVEMBER 11, 2022
LET HEALTH CANADA KNOW WHAT YOU THINK BY TAKING THE SURVEY HERE.
Health Canada wants to end medical cannabis in Canada. They’ve opened up a survey for Canadians to input their opinions. But as is usually the case with these things, the decisions have already been made.
“They’ve always been disingenuous when they put these sorts of surveys out,” says Ted Smith, long-time cannabis activist and contributor to Cannabis Digest. “They’ve really got their minds made up in the position they’re going.”
Medical cannabis patients have a constitutional right to reasonable access. But that doesn’t entail a separate medical program or even the ability to have your cannabis reimbursed through an insurance company.
“The government doesn’t have to do what’s best,” says Ted, “They only have to meet their minimum constitutional standards.”
And with recreational legalization here, Health Canada will likely end medical cannabis.
“I know for certain that Health Canada and their lawyers have been preparing for years to argue that now there’s no need for a distinct medical program,” says Ted.
WHY DOES HEALTH CANADA WANT TO END MEDICAL CANNABIS?
Health Canada Wants to End Medical Cannabis
Since the 1990s, medical cannabis patients have been fighting for their rights. A court decision forced Health Canada to set up a medical cannabis program in 2001.
However, they never approved it as a drug. Doctors only authorize medical cannabis. They don’t prescribe it.
Ted Smith is sure that Health Canada will put medical cannabis under the Natural Health Products Act.
“So if you want to sell something as a cannabis medicine,” says Ted, “you have to go through some testing and be able to say that it’s good for sleep or anxiety. And then you’ll be able to sell it as a cannabis health product. But it won’t be a prescription drug. It’ll be available for anyone over the counter and won’t be available through insurance anymore.”
But why? What’s Health Canada have against medical cannabis? It’s not so much cannabis they don’t like, according to Ted Smith, as it is dealing with patients and their licences.
“They’ve had multiple problems with the whole program,” says Ted. “Partly because it’s been poorly designed from the beginning.”
“From the beginnings of the creation of the MMAR they have said, ‘oh yeah we’re going to listen to members of the public’ but they didn’t create medical stores, didn’t allow for edibles, they didn’t really listen to anybody except the people they wanted to,” says Ted.
HOW HEALTH CANADA WILL END MEDICAL CANNABIS
Health Canada Wants to End Medical Cannabis
How will Health Canada end medical cannabis? By appealing to the recreational market. When Health Canada attempted to remove patient gardens in 2013 with the MMPR, patients responded with the Allard injunction.
The courts sided with patients because, at the time, the medical cannabis market couldn’t provide reasonable access.
“When the Allard decision was made,” says Ted, “patients weren’t getting the strains they needed, they couldn’t get them at the prices they wanted. It was something that was pre-legalization.”
“Now, patients have access to all the strains. They have access to inexpensive cannabis now too compared to what was available. The prices in the legal system are continuing to drop. Not so much for edibles yet, but certainly for the dry herb.”
Ted is confident Health Canada is moving to eliminate the program, which means no more MMAR growers. Since legalization permits four plants per household, the courts may rule that it’s good enough for patients.
Ted also expects legalization rules to change to accommodate patients, but only incremental, superficial changes. Like eight plants instead of four, or 20mg edibles instead of being capped at 10mg.
On a scale of one to ten, how likely will Canadians lose their medical cannabis program?
“I’d say right now the chances are nine,” says Ted. “Because of the general public and the people who have licenses don’t realize how serious of a threat this is.”
WHAT EVIDENCE SUPPORTS HEALTH CANADA?
Health Canada Wants to End Medical Cannabis
“Most of the public and most cannabis consumers have no idea that this is what is in the works,” says Ted. Many medical cannabis patients don’t even realize their gardens are being threatened (again).
And why would the recreational cannabis industry care about Health Canada wanting to end medical cannabis?
“They want the medical program gone too,” says Ted. “They don’t want to give people discounts, they don’t want to answer questions about medical use and do all the extra paper work for medical, they just want to plug stuff out the door fast.”
But you can be sure every police agency, municipality, prescription drug company, and busybody organization knows what’s happening.
“They’re doing everything they can to put evidence forward that Health Canada will be able to then use later in court.”
Medical cannabis patients may have a right to the security of the person. But Health Canada will argue that having a separate medical cannabis program won’t be in the public interest.
“And that’s when all this other evidence that Health Canada is now collecting will be put in play,” says Ted.
So instead of Health Canada’s lawyers doing the legwork, Health Canada “just put a huge net out there and said, ‘hey everybody let us know how you think about this.'”
But in fact, “they’re really just going to be collecting evidence from within the bureaucracy that wants to shut it down.”
WHAT CAN WE DO?
VCBC meets Health Canada
What can we do to ensure Health Canada doesn’t end the medical cannabis program? As mentioned, the survey is more about paying lip service than anything substantial.
That said, it is crucial to let Health Canada know thousands of us are unhappy about this.
The survey wraps up on November 21st, but a week before (November 14th), Ted Smith and associates will make their answers public on Cannabis Digest.
“We want people to see all of our arguments and cut and paste from that and let Health Canada know what’s going on,” says Ted.
“For us, if there’s no medical marijuana program, there are no medical marijuana stores,” which means no more Victoria Cannabis Buyers Club, which has helped countless patients over the years.
Unfortunately, none of this is surprising. When Health Canada receives 90% of its funding from pharmaceutical interests, there will be a conflict of interest.
Ted Smith has long expected how Health Canada wants to end medical cannabis. “We kind have thought they might have done that around the Smith decision,” he says.
But there is good news.
“Many of us that were behind Allard are already ready to go to court after this,” says Ted. “There’s a lot of veterans still here that I’ve been networking with across the country. And so if they do attempt to take away our rights again, there’ll be an injunction applied for it and we’ll go from there.”
Although Ted admits, “it’s going to be a lot more difficult than it was the first time.”
LET HEALTH CANADA KNOW WHAT YOU THINK BY TAKING THE SURVEY HERE.
FOOTNOTE(S)
https://cannabisdigest.ca/recreational-market-ready-to-dismantle-medical-cannabis-market/
https://cannabisdigest.ca/health-canada-and-doctors-fight-against-med-pot-program/
https://www.canada.ca/en/health-canada/programs/engaging-cannabis-legalization-regulation-canada-taking-stock-progress.html
https://datac.ca/health-canada-switches-mainly-pharmaceutical-funding/
It has been recalled. Mold city. Doomed.
Cannabis May Benefit the Middle-Aged Brain
https://www.psychologytoday.com/gb/blog/your-brain-food/202211/cannabis-may-benefit-the-middle-aged-brain
And nobody here will know because the chart associated with this stock is not here.
We knew that all along without any research.
Lol.
With cannabis, the proof is in the pudding.
Easy cheesy!
New research disputes the “lazy stoner” stereotype
https://www.psypost.org/2022/11/new-research-disputes-the-lazy-stoner-stereotype-64265
Most Voters In Two States That Defeated Marijuana Ballot Measures Actually Support Legalization In General,
https://www.marijuanamoment.net/most-voters-in-two-states-that-defeated-marijuana-ballot-measures-actually-support-legalization-in-general-election-poll-finds/
Wisconsin Governor Pledges To Put Marijuana Legalization In Upcoming Budget After Voters Approve Reform On The Ballot
https://www.marijuanamoment.net/wisconsin-governor-pledges-to-put-marijuana-legalization-in-upcoming-budget-after-voters-approve-reform-on-the-ballot/
Followers
|
666
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
128490
|
Created
|
03/18/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |